4 unknown, 2 not yet recruiting, 2 recruiting, 1 terminated. 9 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Unknown 4, Not yet recruiting 2, Recruiting 2, Terminated 1 |
| Phase 1 | 8 | Unknown 4, Not yet recruiting 2, Recruiting 1, Terminated 1 |
Follow CAR-T cells: new trials by email Literature Review of CAR-T cells trials Research Report on CAR-T cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-11-02 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP) CAR-T cells - ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 10 | 2024-02-01 | 2024-07-22 |
| To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) CAR-T cells - Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | National University of Malaysia | 20 | 2021-06-03 | 2024-11-21 |
| Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions CAR-T cells - Hematological Malignancies | Phase 1 / Phase 2 | Unknown | Zhejiang University | 50 | 2021-03-01 | 2021-03-10 |
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma MLM-CAR44.1 T-cells at day 0 Single intravenous infusion - Acute Myeloid Leukemia, Multiple Myeloma | Phase 1 / Phase 2 | Terminated | AGC Biologics S.p.A. | 8 | 2019-08-27 | 2022-01-19 |
| Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC CAR-T Cells, CAR-T combining PD-1 Knockout, PD-1 knockout - Lung Neoplasm Malignant, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Guangdong Pharmaceutical University | 60 | 2018-02-01 | 2018-05-16 |
| A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application CAR-T cells - Nasopharyngeal Neoplasms | Phase 1 / Phase 2 | Unknown | The Second Hospital of Nanjing Medical University | 20 | 2016-11-01 | 2016-12-02 |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies Second generation CAR-T cells - Acute Lymphoblastic Leukemia, B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Wuhan Sian Medical Technology Co., Ltd | 80 | 2015-12-02 | 2019-05-10 |
Multiple Myeloma (3) · Lymphoma, B-Cell (2) · Recurrence (2) · Carcinoma, Non-Small-Cell Lung (1) · Hematologic Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Plasmacytoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Purpura, Thrombocytopenic, Idiopathic (1)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · AGC Biologics S.p.A. (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · National University of Malaysia (1) · Shenzhen Geno-Immune Medical Institute (1) · The First Affiliated Hospital of Guangdong Pharmaceutical University (1) · The Second Hospital of Nanjing Medical University (1) · Wuhan Sian Medical Technology Co., Ltd (1) · Zhejiang University (1)
China (6) · Czechia (1) · France (1) · Italy (1) · Malaysia (1)
Fabio Ciceri, MD (1) · Sanbin Wang, Doctor (1) · Yu Hu, M.D., Ph.D (1)
PMID 33554732, PMID 35799791, PMID 38321811, PMID 40195173
2018 (1), 2025 (1)